drugset / Trial / NCT01394562

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure

NCT01394562

Phase 3 Completed 174 enrolled Vifor Pharma
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to confirm that treatment with IV ferric carboxymaltose improves exercise capacity, physical functioning and quality of life in patients with iron deficiency and chronic heart failure.

Timeline

Start
2011-07
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric carboxymaltose Other / unclassified Intravenous